Selank Nasal Spray
Selank nasal spray represents a stabilized intranasal liquid formulation of the synthetic heptapeptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), an analog of the naturally occurring immunomodulatory peptide tuftsin. Developed strictly for in vitro and animal research, intranasal delivery systems permit investigators to study direct nose-to-brain peptide transport, central GABAergic modulation, and neurotrophic factor expression without invasive parenteral administration.
Quick answer
Selank nasal spray represents a stabilized intranasal liquid formulation of the synthetic heptapeptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), an analog of the naturally occurring immunomodulatory peptide tuftsin. Developed strictly for in vitro and animal research, intranasal delivery systems permit investigators to study direct nose-to-brain peptide transport, central GABAergic modulation, and neurotrophic factor expression without invasive parenteral administration.
Key takeaways
- [Selank](/research-peptides/selank) is a synthetic heptapeptide with the primary amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro.
- Preclinical literature demonstrates that [Selank](/research-peptides/selank) exerts complex, multi-target neuromodulatory effects across several central signaling pathways.
- In addition to classical neurotransmitter modulation, preclinical studies highlight [Selank](/research-peptides/selank)'s capacity to influence gene expression profiles related to neuroplasticity and neuronal survival.
- The development of intranasal liquid configurations—commonly designated in research as a nasal spray—addresses the challenge of delivering intact polar peptides across the blood-brain barrier (BBB).
Biochemical Structure and Origin of Selank
Selank is a synthetic heptapeptide with the primary amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Derived from the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg), which constitutes a natural fragment of the human immunoglobulin G (IgG) heavy chain, Selank was engineered by incorporating a Pro-Gly-Pro C-terminal tripeptide extension. This structural modification was designed to significantly enhance metabolic stability against circulating carboxypeptidases and aminopeptidases, extending the peptide's enzymatic half-life in physiological media while retaining its core biological affinity.
In laboratory investigations, the structural stability of the Pro-Gly-Pro motif allows researchers to evaluate peptide dynamics without the rapid enzymatic cleavage typically observed with unmodified tuftsin fragments. When solubilized into a specialized aqueous vehicle for intranasal administration, Selank solution provides a stable matrix for examining direct mucosal absorption and targeted transport into the central nervous system (CNS).
Mechanisms of Action in Preclinical Models
Preclinical literature demonstrates that Selank exerts complex, multi-target neuromodulatory effects across several central signaling pathways. Unlike conventional GABAergic agents that bind directly to benzodiazepine site receptors, in vitro receptor binding assays indicate that Selank modulates gamma-aminobutyric acid (GABA) neurotransmission via indirect, allosteric mechanisms. Research models show that Selank alters the affinity of GABA_A receptors for endogenous ligands, stabilizing inhibitory signaling cascades without inducing receptor downregulation or tolerance over extended experimental timelines.
Beyond GABAergic interactions, biochemical evaluations demonstrate that Selank acts as an inhibitor of enkephalin-degrading enzymes, specifically neutral endopeptidase (NEP) and carboxypeptidase N. By suppressing the enzymatic degradation of endogenous leu-enkephalin and met-enkephalin in blood plasma and tissue homogenates, Selank elevates endogenous opioid peptide availability. Researchers frequently study this dual GABAergic-enkephalinergic axis within our broader catalog of neuroactive peptides to determine how peptide fragments regulate stress-response pathways in rodent models.
Neurotrophic Dynamics and BDNF Gene Expression
In addition to classical neurotransmitter modulation, preclinical studies highlight Selank's capacity to influence gene expression profiles related to neuroplasticity and neuronal survival. Microarray and quantitative PCR (qPCR) analyses in murine cerebral cortex models demonstrate that acute administration of Selank rapidly upregulates the transcription of brain-derived neurotrophic factor (BDNF) and its primary receptor, tropomyosin receptor kinase B (TrkB).
This transient spike in BDNF mRNA expression correlates with enhanced dendritic spine density and synaptogenesis in hippocampal cell cultures. Investigating these genomic response patterns allows researchers utilizing the PX1 Research library hub to evaluate how short-chain peptide signaling cascades preserve neuronal architecture under conditions of induced excitotoxicity, metabolic stress, or cellular hypoxia.
Intranasal Administration and Nose-to-Brain Transport Bioavailability
The development of intranasal liquid configurations—commonly designated in research as a nasal spray—addresses the challenge of delivering intact polar peptides across the blood-brain barrier (BBB). Non-invasive intranasal administration takes advantage of the olfactory and trigeminal neural pathways that directly connect the nasal respiratory epithelium to the olfactory bulb and brainstem, bypassing systemic circulation and hepatic first-pass metabolism.
Preclinical pharmacokinetic studies using radiolabeled or fluorescently tagged Selank reveal that intranasal deposition achieves higher relative concentration AUC (area under the curve) values in the olfactory bulb, hippocampus, and frontal cortex compared to equivalent intravenous or intraperitoneal doses. This localized delivery profile reduces systemic off-target exposure while allowing precise quantification of central tissue distribution in animal models.
Comparative Analysis: Selank vs. Semax and Related Compounds
Within neurobiology literature, Selank is frequently evaluated alongside other synthetic peptide analogs derived from endogenous regulators. A notable comparator is Semax, an heptapeptide analog of ACTH(4-10). While both peptides incorporate a Pro-Gly-Pro stabilizing sequence at their C-terminus and share neuroprotective research applications, their primary target pathways differ substantially.
Whereas Selank predominantly influences GABAergic allosteric binding, enkephalinase inhibition, and selective BDNF expression, Semax acts primarily through melanocortin receptor activation, neurotrophin modulation (NGF/BDNF), and dopaminergic neurotransmission. For comparative studies evaluating tissue healing or peripheral signaling alongside neuroprotection, investigators often analyze these compounds against regenerative peptides such as BPC-157. A detailed breakdown of structural distinctions and receptor affinities can be reviewed in our comparative Semax vs Selank research guide.
Formulation Dynamics and Intranasal Solution Stability
Preparing a stable liquid matrix for intranasal research requires strict control over pH, osmolarity, and peptide solubility. Lyophilized Selank acetate must be reconstituted using sterile, non-pyrogenic vehicles such as bacteriostatic water, sterile 0.9% sodium chloride, or buffered saline solutions to match the physiological conditions of mucosal membranes (pH 5.5 to 6.5).
Because peptides in aqueous solution are susceptible to hydrolysis and oxidative degradation over time, research protocols must account for temperature control and container interaction. Utilizing high-density polyethylene (HDPE) or glass metered-dose spray assemblies ensures precise volumetric discharge per actuation (typically 100 µL per spray) while preventing peptide adsorption to container walls during longitudinal studies.
Analytical Verification and Quality Control Metrics
To guarantee reproducible scientific data, research compounds must satisfy rigorous analytical benchmarks prior to experimental deployment. At PX1 Research, every batch of Selank undergoes mandatory testing protocol execution in ISO 17025 accredited, third-party laboratories. Purity is established via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a baseline chemical purity of equal to or greater than 99.0%.
Identity and exact molecular weight are confirmed through Electrospray Ionization Mass Spectrometry (ESI-MS), matching the theoretical monoisotopic mass of the Selank sequence. Crucially, given that intranasal formulations directly contact mucosal surfaces in preclinical models, bacterial endotoxin content is rigorously quantified using Chromogenic LAL (Limulus Amebocyte Lysate) assays to ensure levels remain strictly under <0.5 EU/mg. Batch-specific Certificates of Analysis (COAs) containing raw chromatograms are publicly published for total lot traceability.
Storage and Handling Protocols for Laboratory Research
Lyophilized Selank powder should be stored at -20°C in a dry, dark environment away from direct light exposure to maintain long-term peptide integrity. Under these storage conditions, the dry peptide remains stable for up to 24 months. Repeated freeze-thaw cycles must be avoided, as thermal fluctuations promote aggregation and peptide cleavage.
Once reconstituted into an aqueous intranasal solution, the compound must be kept refrigerated at 2°C to 8°C and used within a defined experimental window (typically 30 to 45 days). For long-term project planning or institutional procurement, laboratory managers can coordinate bulk supply constraints directly through our bulk research peptide account desk.
PX1 Research Supply Standards and Manufacturing Integrity
PX1 Research operates as a trusted USA-based supplier dedicated exclusively to supporting academic, clinical, and institutional research endeavors. All research peptides are manufactured in state-of-the-art, GMP-compliant facilities located within the United States. We maintain strict separation between industrial chemical synthesis and analytical verification, ensuring that no unverified material enters our distribution pipeline.
Orders placed before standard cutoffs ship same-day (Monday through Friday) directly from our centralized distribution facilities in California and Arizona. Every package features temperature-monitored, secure packaging to safeguard peptide structure during transit, ensuring that your laboratory receives pristine, fully verified reagents ready for controlled experimental protocols.
Frequently Asked Questions
What is Selank nasal spray used for in preclinical research?
Selank nasal spray is an intranasal research solution used in laboratory models to investigate direct nose-to-brain peptide transport, central GABAergic allosteric modulation, enkephalinase enzyme inhibition, and BDNF gene expression upregulation.
How does Selank differ structurally from Semax?
Selank is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the immunomodulator tuftsin, whereas Semax is derived from an ACTH(4-10) fragment. Both feature a C-terminal Pro-Gly-Pro sequence for enzymatic stability but target different central neurochemical systems.
What analytical methods verify the purity of PX1 Research Selank?
Every lot of Selank undergoes independent ISO 17025 laboratory testing using RP-HPLC to confirm ≥99% purity, ESI-MS mass spectrometry to confirm molecular identity, and Chromogenic LAL testing to verify endotoxin levels are <0.5 EU/mg.
What vehicle is recommended for reconstituting Selank into a spray?
For laboratory applications, lyophilized Selank is typically reconstituted using sterile 0.9% sodium chloride, bacteriostatic water, or phosphate-buffered saline (PBS) formulated to maintain a stable mucosal pH of 5.5 to 6.5.
How should reconstituted Selank liquid solutions be stored?
Reconstituted Selank intranasal solutions must be refrigerated at 2°C to 8°C, protected from light, and utilized within 30 to 45 days to minimize hydrolytic degradation. Unreconstituted lyophilized powder should be stored at -20°C.
What is the endotoxin limit for research-grade Selank?
PX1 Research enforces a strict endotoxin limit of less than 0.5 EU/mg for all research peptides, ensuring that cell culture and animal models are free from pyrogen-induced inflammatory confounds.
Can Selank be ordered in bulk for institutional studies?
Yes, institutions and laboratory purchasing agents can establish dedicated accounts for bulk peptide supply and custom batch fulfillment via our wholesale portal.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities and shipped same-day (M–F) from fulfillment centers located in California and Arizona.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.